Current Issue

Dear Editor, A recent editorial by Hajjar[1] concisely highlighted the key challenges of cancer immunotherapy in immunocompromised patients. We wish to expand on those emerging issues and their rel...

We have read with great interest the recent issue of the Journal of Immunotherapy and Precision Oncology, which is edited by Dr. Joud Hajjar. It illuminated the area of cancer immunotherapy in immun...

Introduction: Invasive micropapillary carcinoma (IMPC) of the breast is a rare and aggressive subtype of invasive ductal carcinomas, associated with poor prognosis and without a well-establis...

Background: Polymorphism within the human T-cell receptor beta variable (TRBV) gene has been proposed as a risk factor for autoimmune disease and immune-related adverse events (IRAEs) during ...

Immune checkpoint inhibitors benefit a proportion of patients with cancer, but not all patients nor all histologies will respond to immunotherapy. Therefore, predictive biomarkers are needed. In thi...